Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 14K | 33K | 0 |
| Gross Profit | 1K | 17K | 0 |
| Operating Income | -2M | -120K | -180K |
| EBITDA | -2M | 622K | -180K |
| Net Income | -2M | 410K | -210K |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$0.0003
+0.00% today
1Y Change
+200.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wuhan General Group (China), Inc. (WUHN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 200.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -57.4%, EPS growth of -494.9%, a dividend yield of 0.0%. What stands out right now is revenue -57.4%, EPS -494.9%, free cash flow -3251.2% with operating margin -11882.9% and ROIC -254.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WUHN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WUHN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WUHN Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WUHN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$210.4K
-151.3% YoY
Free Cash Flow
-$306.6K
-681.7% YoY
Revenue Growth
-57.4%
EPS Growth
-494.9%
Gross Margin
9.7%
Net Margin
-12086.9%
Income statement
USD
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 14K | 33K | 0 |
| Gross Profit | 1K | 17K | 0 |
| Operating Income | -2M | -120K | -180K |
| EBITDA | -2M | 622K | -180K |
| Net Income | -2M | 410K | -210K |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Cash & Equivalents | 108K | 159K | 6K |
| Total Assets | 764K | 597K | 84K |
| Total Liabilities | 186K | 90K | 659K |
| Shareholder Equity | 577K | 507K | -575K |
| Total Debt | 84K | 86K | 656K |
| Net Debt | -24K | -73K | 650K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
307K
-681.7% YoY
Capital Expenditures
0
Free Cash Flow
307K
-681.7% YoY
Key ratios
Gross Margin
9.7%
Operating Margin
-11882.9%
Net Margin
-12086.9%
ROE
-316.1%
Debt / Equity
0.15x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.